Report Sections

See All Reports

  • HP:0012174: Glioblastoma multiforme
  • Pneumonia (382) Neoplasm (47) Respiratory tract infection (46) Diabetes mellitus (39) Abnormality of the cardiovascular system (39) Depressivity (35) Abnormal lung morphology (33) Hypoxemia (30) Acute kidney injury (29) Hypertension (25) Thromboembolism (23) Myocardial infarction (22) Anosmia (21) Mental deterioration (21) Arthritis (20) Type II diabetes mellitus (20) Chronic pulmonary obstruction (19) Leukemia (18) Pulmonary fibrosis (18) Pulmonary obstruction (18) Abnormality of the kidney (17) Stroke (17) Congestive heart failure (16) Abnormality of coagulation (16) Pulmonary embolism (16) Neoplasm of the lung (16) Rheumatoid arthritis (15) Asthma (15) Interstitial pneumonitis (15) Crohn's disease (15) Autistic behavior (14) Chronic pain (14) Type I diabetes mellitus (13) Deep venous thrombosis (12) Ulcerative colitis (12) Autism (11) Obesity (11) Respiratory distress (11) Colitis (11) Carcinoma (11) Alzheimer disease (10) Lymphoma (10) Chronic kidney disease (10) Myocarditis (10) Low levels of vitamin D (10) Sepsis (10) Renal insufficiency (9) Dementia (9) Abnormality of the liver (9) Coronary artery atherosclerosis (9) Weight loss (9) Inflammation of the large intestine (9) Pulmonary insufficiency (9) Behavioral abnormality (8) Psychosis (8) Infertility (8) Abnormality of the gastrointestinal tract (8) Migraine (7) Breast carcinoma (7) Psoriasiform dermatitis (7) Peripheral arterial stenosis (7) Fatigue (7) Schizophrenia (7) Encephalopathy (6) Lymphopenia (6) Dysphagia (6) Bronchiectasis (6) Immunodeficiency (6) Systemic lupus erythematosus (6) Osteoarthritis (6) Obstructive sleep apnea (6) Sleep apnea (6) Prostate cancer (6) Non-small cell lung carcinoma (6) Neoplasm of the large intestine (6) Seizure (5) Premature birth (5) Difficulty walking (5) Gastroparesis (5) Neoplasm of the pancreas (5) Autoimmunity (5) Knee osteoarthritis (5) Disseminated intravascular coagulation (5) Lymphoid leukemia (5) Inflammatory abnormality of the skin (5) Neoplasm of head and neck (5) Allergy (5) Eczema (4) Atopic dermatitis (4) Hepatic fibrosis (4) Cardiac arrest (4) Abnormality of blood and blood-forming tissues (4) Pulmonary arterial hypertension (4) Abnormal intestine morphology (4) Headache (4) Colon cancer (4) Reduced factor VIII activity (4) Malnutrition (4) Paroxysmal atrial fibrillation (4) Renal cell carcinoma (4) Abnormal anterior horn cell morphology (4) Attention deficit hyperactivity disorder (4) Amyotrophic lateral sclerosis (4) Arrhythmia (4) Endometriosis (4) Addictive behavior (4) Hypercoagulability (4) Insomnia (4) Abnormality of the eye (3) Obsessive-compulsive behavior (3) Abnormality of the endocrine system (3) Spastic diplegia (3) Polyneuropathy (3) Meningitis (3) Hepatic steatosis (3) Abnormal heart morphology (3) Cardiomyopathy (3) Tachycardia (3) Fever (3) Hypothermia (3) Apnea (3) Celiac disease (3) Myelodysplasia (3) Acute myeloid leukemia (3) Myeloproliferative disorder (3) Chronic lymphatic leukemia (3) Multiple myeloma (3) Cystoid macular edema (3) Postprandial hyperglycemia (3) Cutaneous melanoma (3) Small cell lung carcinoma (3) Pulmonary edema (3) Ovarian neoplasm (3) Neuroendocrine neoplasm (3) Bulimia (3) Hypogeusia (2) Hearing impairment (2) Visual impairment (2) Conjunctivitis (2) Cataract (2) Uveitis (2) Periodontitis (2) Agoraphobia (2) Nephrolithiasis (2) Abnormality of the thyroid gland (2) Abnormality of the skin (2) Jaundice (2) Lymphedema (2) Keratoconjunctivitis sicca (2) Spasticity (2) Hemiparesis (2) Abnormal joint morphology (2) Aortic valve stenosis (2) Angina pectoris (2) Pancreatitis (2) Thrombocytopenia (2) Autoimmune thrombocytopenia (2) Gout (2) Diarrhea (2) Gastroesophageal reflux (2) Neurodegeneration (2) Alopecia of scalp (2) Mutism (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Hypotension (2) Atherosclerosis (2) Hypoventilation (2) Squamous cell carcinoma (2) Male infertility (2) Back pain (2) Low back pain (2) Muscular dystrophy (2) Stillbirth (2) Chronic bronchitis (2) Lymphoproliferative disorder (2) Intervertebral disc degeneration (2) Stomatitis (2) Stridor (2) Hemeralopia (2) Arteritis (2) Hepatitis (2) Glioblastoma multiforme (2) B-cell lymphoma (2) Myeloid leukemia (2) Bronchitis (2) Pain (2) Cervix cancer (2) Cholangitis (2) Endocarditis (2) Toxemia of pregnancy (2) Myositis (2) Mania (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Otitis media (1) Conductive hearing impairment (1) Amblyopia (1) Abnormality of the nervous system (1) Aggressive behavior (1) IgA deposition in the glomerulus (1) Oligospermia (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Urticaria (1) Angiokeratoma corporis diffusum (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Syncope (1) Cerebral hemorrhage (1) Hepatic failure (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Cor pulmonale (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Premature rupture of membranes (1) Iron deficiency anemia (1) Anemia (1) Dehydration (1) Constipation (1) Anorexia (1) Esophageal varix (1) Chorea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Abnormality of the spinal cord (1) Hyperkalemia (1) Memory impairment (1) Encephalitis (1) Spina bifida (1) Language impairment (1) Myelomeningocele (1) Waddling gait (1) Increased intracranial pressure (1) Biliary cirrhosis (1) Vascular dilatation (1) Recurrent E. coli infections (1) Osteomyelitis (1) Tachypnea (1) Central apnea (1) Embryonal neoplasm (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Allergic rhinitis (1) Skeletal muscle atrophy (1) Spondylolisthesis (1) Myalgia (1) Bruxism (1) Neonatal death (1) Increased body weight (1) Enterocolitis (1) Intermittent claudication (1) Thrombophlebitis (1) Supraventricular tachycardia (1) Ventricular tachycardia (1) Acute myelomonocytic leukemia (1) Dilatation of the cerebral artery (1) Coronary artery stenosis (1) Spontaneous abortion (1) Venous insufficiency (1) Monoclonal immunoglobulin M proteinemia (1) Abnormality of bone marrow cell morphology (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Bladder neoplasm (1) Uterine neoplasm (1) Intestinal atresia (1) Tonsillitis (1) Placental abruption (1) Sinus tachycardia (1) Bronchiolitis (1) Erythroid hypoplasia (1) Asterixis (1) Hodgkin lymphoma (1) Ciliary dyskinesia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Rhinitis (1) Seasonal allergy (1) Hypercapnia (1) Restless legs (1) Non-Hodgkin lymphoma (1) Membranous nephropathy (1) Retinal vein occlusion (1) Vasovagal syncope (1) Heart block (1) Cough (1) Neonatal asphyxia (1) Dyspareunia (1) Ductal carcinoma in situ (1) Heart murmur (1) Cardiogenic shock (1) Cholangiocarcinoma (1) Vulvar neoplasm (1) Brain neoplasm (1) Femur fracture (1) Neonatal sepsis (1) Glue ear (1) Abnormality of movement (1) Sarcoma (1) Subdural hemorrhage (1) Biliary tract neoplasm (1) Nasal polyposis (1) Rectal fistula (1) Eclampsia (1) Esophagitis (1) Vaginal neoplasm (1) Cellulitis (1) Angioedema (1) Self-injurious behavior (1) Gastrointestinal stroma tumor (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Halitosis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0012174: Glioblastoma multiforme

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (7)


    Name (Synonyms) Correlation
    drug4107 Standard of Care (SOC): Radiation Therapy Wiki 0.71
    drug3612 Reduced Dose Bevacizumab Wiki 0.71
    drug2027 IGV-001 Cell Immunotherapy Wiki 0.71
    Name (Synonyms) Correlation
    drug4075 Standard Dose Bevacizumab Wiki 0.71
    drug3832 SOC: Temozolomide Wiki 0.71
    drug2819 Nivolumab Wiki 0.41
    drug3195 Placebo Wiki 0.03

    Correlated MeSH Terms (1)


    Name (Synonyms) Correlation
    D005909 Glioblastoma NIH 1.00

    Correlated HPO Terms (0)


    Name (Synonyms) Correlation

    Clinical Trials

    Navigate: Correlations   HPO

    There are 2 clinical trials


    1 CA209-382 A Randomized Phase 2 Open Label Study of Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in Recurrent Glioblastoma (GBM)

    The purpose of this study is to test the effectiveness (how well the drug works), safety and tolerability of an investigational drug called nivolumab (also known as BMS-936558) in glioblastoma (a malignant tumor, or GBM), when added to bevacizumab. Nivolumab is an antibody (a kind of human protein) that is being tested to see if it will allow the body's immune system to work against glioblastoma tumors. Opdivo (Nivolumab) is currently FDA approved in the United States for melanoma (a type of skin cancer), non-small cell lung cancer, renal cell cancer (a type of kidney cancer), Hodgkin's lymphoma but is not approved in glioblastoma. Nivolumab may help your immune system detect and attack cancer cells. Bevacizumab is a drug which works on the blood vessel that supply the tumor and potentially can starve the tumor by cutting off the blood supply to these tumors. Bevacizumab is commercially available and FDA approved for patients with recurrent glioblastoma. This study has two study groups. Arm 1 will receive the study drug Nivolumab 240mg and bevacizumab 10 mg (standard dose) every 2 weeks and Arm 2 will receive the study drug Nivolumab 240 mg and bevacizumab 3 mg (reduced dose) every 2 weeks. A process will be used to assign patients, by chance, to one of the study groups. Neither patients nor doctors can choose which group patients are in. This is done by chance because no one knows if one study group is better or worse than the other. 90 total patients are expected to participate in this study (45 patients in each arm). Your total participation in this study from the time you have signed the informed consent to your last visit, including follow-up visits, may be more than three years (depending on what effect the treatment has on your cancer, and how well you tolerate the treatment).

    NCT03452579
    Conditions
    1. Glioblastoma
    Interventions
    1. Drug: Nivolumab
    2. Drug: Standard Dose Bevacizumab
    3. Drug: Reduced Dose Bevacizumab
    MeSH:Glioblastoma
    HPO:Glioblastoma multiforme

    Primary Outcomes

    Description: The proportion of subjects in the analysis population who remain alive for at least twelve months following initiation of study therapy.

    Measure: Overall Survival at 12 Months

    Time: Up to 12 months after beginning therapy

    Secondary Outcomes

    Description: Time from beginning of treatment to death

    Measure: Overall Survival

    Time: Up to 3 years after beginning treatment

    Description: Proportion of subjects in the analysis population who have complete response (CR) or partial response (PR) using Radiologic Assessment in Neuro-Oncology criteria (RANO) criteria.

    Measure: Overall Response Rate

    Time: Up to 3 years after beginning treatment

    Description: Time from first RANO response to disease progression in subjects who achieve a PR or better

    Measure: Duration of Response

    Time: Up to 3 years after beginning treatment

    Description: Defined as the time from allocation to the first documented disease progression according to RANO or death due to any cause, whichever occurs first

    Measure: Progression-Free Survival

    Time: Up to 3 years after beginning treatment

    Description: The proportion of subjects in the analysis population who remain progression-free for at least six months following initiation of study therapy

    Measure: Progression-Free Survival at Six Months

    Time: Up to six months after beginning treatment
    2 A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma Multiforme - the ImmuneSense Study

    The purpose of this study is to assess progression-free survival (PFS) in newly diagnosed Glioblastoma Multiforme (GBM) participants treated with IGV-001 as compared with placebo.

    NCT04485949
    Conditions
    1. Glioblastoma Multiforme
    2. Glioblastoma
    Interventions
    1. Biological: IGV-001 Cell Immunotherapy
    2. Biological: Placebo
    3. Procedure: Standard of Care (SOC): Radiation Therapy
    4. Drug: SOC: Temozolomide
    MeSH:Glioblastoma
    HPO:Glioblastoma multiforme

    Primary Outcomes

    Description: PFS is defined as the time from randomization to event or censoring.

    Measure: Progression-free Survival (PFS)

    Time: Up to 36 months

    Secondary Outcomes

    Description: OS is defined as the time from randomization to death due to any cause.

    Measure: Overall Survival (OS)

    Time: Up to 48 months

    Description: PFS is defined as the time from randomization to event or censoring. MGMT status will be determined per epigenetic analysis from tissue obtained during surgery.

    Measure: PFS in Participants With O6-methylguanine-DNA Methyltransferase (MGMT) With Methylation [MGMT+] and MGMT Without Methylation [MGMT-]

    Time: Up to 36 months

    Description: OS is defined as the time from randomization to death due to any cause. MGMT status will be determined per epigenetic analysis from tissue obtained during surgery.

    Measure: OS in Participants With MGMT+ and MGMT-

    Time: Up to 48 months

    Description: EORTC QLQ-C30 contains 30 items across 5 functional scales (physical, role, cognitive, emotional, and social), 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status/QOL scale. EORTC QLQ-C30 contains 28 questions (4-point scale where 1=Not at all [best] to 4=Very Much [worst]) and 2 questions (7-point scale where 1=Very poor [worst] to 7= Excellent [best]). Raw scores are converted into scale scores ranging from 0 to 100. For the functional scales and the global health status/QOL scale, higher scores represent better QOL; for the symptom scales, lower scores represent better QOL.

    Measure: Change From Baseline in Participant-reported Quality of Life (QoL) Questionnaires Based on European Organization for Research and Treatment of Cancer (EORTC) Quality of Lif questionnaire (QLQ) -C30 Scores

    Time: Baseline, Month 36

    Description: The QLQ-BN20 is a questionnaire specifically designed as the QLQ-C30 supplement for the evaluation of quality of life in brain tumor participants. It includes 4 multi-item sub-scales: future uncertainty, visual disorder, motor dysfunction, communication deficits, and 7 single-item scales: headaches, seizures, drowsiness, itchy skin, hair loss, weakness of legs, and bladder control. All items are rated on a 4-point Likert-type scale ('1=not at all', '2=a little', '3=quite a bit' and '4=very much'), and are linearly transformed to a 0-100 scale, with higher scores indicating more severe symptoms.

    Measure: Change From Baseline in Participant-reported QoL Questionnaires Based on EORTC QLQ Brain Module (EORTC QLQ-BN20) Scores

    Time: Baseline, Month 36

    Description: The MMSE is an instrument used to assess a participant's global cognitive function. The MMSE assesses orientation to time and place, immediate and delayed recall of words, attention and calculation, language (naming, comprehension and repetition), and spatial ability (copying a figure). The range for MMSE total Score is 0 to 30, with a higher score indicating better cognitive performance.

    Measure: Change From Baseline in Mini-Mental Status Examination (MMSE) Scores

    Time: Baseline, Month 36

    Description: Time to KPS deterioration was defined as the time from screening to the first date of deterioration of the KPS score. Deterioration of KPS is defined as a stable or increasing steroid dose-dependent stabilization of a KPS score of <70 over 2 consecutive visits no more than 2 months apart. KPS is an 11-level score which ranges between 0 (death) to 100 (complete healthy status); a higher score represents a higher ability to perform daily tasks.

    Measure: Time to Definitive Deterioration Karnofsky Performance Status (KPS) Score

    Time: Baseline until KPS deterioration (up to 36 months)

    Description: An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. AEs will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0 from mild (Grade 1) to death (Grade 5). SAE is an AE or adverse reaction which is considered serious if it results in any of the following outcomes: death, life-threatening AE, require hospitalizations or prolongation of hospitalizations, results in persistent or significant disability/incapacity; results in a congenital anomaly/birth defect and is a medically important event.

    Measure: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time: Up to 12 months or until the last progression visit, whichever comes first

    Measure: Number of Participants With Clinically Significant Laboratory Assessment Abnormalities

    Time: Up to 12 months or until the last progression visit, whichever comes first

    Measure: Number of Participants With Clinically Significant Vital Signs Measurements

    Time: Up to 12 months or until the last progression visit, whichever comes first

    Measure: Number of Participants With Clinically Significant Physical Examination Findings

    Time: Up to 12 months or until the last progression visit, whichever comes first

    HPO Nodes


    Reports

    Data processed on December 13, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook